Opus Genetics’ VEGA-3 Trial Hits Primary Endpoint for Phentolamine 0.75% for Presbyopia
Phentolamine 0.75% improved near vision at 12 hours post-dose on Day 8. Opus Genetics (North Carolina, United States) has announced…
Research Illuminates Gender and Racial Disparities in Ophthalmology Resident Surgical Volume
A new study in JAMA cuts deep into who’s getting surgical reps and who’s getting left behind. Turns out, not…